

#3
6/12/02
83

PATENT
Customer No. 22,852
Attorney Docket No. 02481.1768-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc Nazaré, et al) Group Art Unit: To be assigned
)
Application No.: To be assigned) Examiner: To be assigned
)
Filed: December 21, 2001)
)
For: New Oxybenzamide Derivatives)
Useful for Inhibiting Factor Xa or VIIa)

3530 U.S. PRO
10/023933
12/21/01

Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed within three months of the filing date of the above-referenced application. Copies of the listed documents are attached.

In lieu of a translation of EP 0019589, Applicants have provided US Patent Nos. 4,568,636 and 4,428,874, which are believed to be the English language equivalents of EP 0019589. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 21, 2001

By: 
Carol P. Einaudi
Reg. No. 32,220

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1768-00000	Serial No.	To be assigned
Applicant	Marc Nazaré, et al		
Filing Date	December 21, 2001	Group:	To be assigned

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	4,309,212	Jan. 5, 1982	Takemoto, et al	71	120	
	4,428,874	Jan. 31, 1984	Svensen	260	112.5	
	4,568,636	Feb. 4, 1986	Svensen	435	13	

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
EP 0019589	Nov. 26, 1980	Germany			No
GB 2011892	July 18, 1979	United Kingdom			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Bilstein Registry No. 95671, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 146145, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 869622, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 1430606, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 3069936, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 4301943, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 7062387, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 7813412, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8326226, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8331996, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8360262, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1768-00000	Serial No.	To be assigned
Applicant	Marc Nazaré, et al		
Filing Date	December 21, 2001	Group:	To be assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Bilstein Registry No. 8511019, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8523212, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8564005, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8639815, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8653610, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8658351, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
	Bilstein Registry No. 8665019, Database Crossfire Bilstein, Beilstein Institut Zur Foerderung Der Wissenschaften, Frankfurt, Germany.
✓	Bailey, et al., <i>Angewandte Chemie</i> , 39: 506-508 (2000).
✓	Campillo, et al., <i>Journal Medicinal Chemistry</i> , 42: 3279-3288 (1999).
✓	Choi-Sledeski, et al., <i>Bioorganic and Medicinal Chemistry Letters</i> , 9: 2539-2544 (1999).
✓	European Search Report dated Oct 29, 2001, for European Patent Application No. 00/128477.
✓	Fujio, et al., <i>Bioorganic and Medicinal Chemistry Letters</i> , 10: 2457-2461 (2000).
✓	Hanessian, et al., <i>Bioorganic and Medicinal Chemistry Letters</i> , 10: 243-247 (2000).
✓	He, et al., <i>Bioorganic and Medicinal Chemistry Letters</i> , 10: 1737-1739 (2000).
✓	Herron, et al., <i>J. Med. Chem.</i> , 43: 859-872 (2000).
✓	Hoekstra, et al., <i>J. Med. Chem.</i> , 42: 5254-5265 (1999).
✓	Maignan, et al., <i>J. Med. Chem.</i> , 43: 3226-3232 (2000).
✓	Ogino, et al., <i>Bioorganic and Medicinal Chemistry Letters</i> , 8:75-80 (1998).
✓	Okada, et al., <i>Bioorganic and Medicinal Chemistry Letters</i> , 10: 2217-2221 (2000).
✓	Pitts, et al., <i>J. Med. Chem.</i> , 43: 27-40 (2000).
✓	Rehse, et al., <i>Archiv der Pharmazie</i> , 333: 157-161 (2000).
✓	Roussel, et al., <i>Tetrahedron</i> , 55: 6219-6230 (1999).
✓	Walser, et al., <i>J. Med. Chem.</i> , 34: 1209-1221 (1991).

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	02481.1768-00000	Serial No.	To be assigned
Applicant	Marc Nazaré, et al		
Filing Date	December 21, 2001	Group:	To be assigned
Examiner	Date Considered		
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce		